Abstract Background Chronic Myeloid Leukemia (CML) is characterized by the
overproduction of BCR-ABL, a tyrosine kinase with constitutive activity, in which the majority …

Although the majority of patients with chronic myeloid leukemia do well with treatment with
tyrosine kinase inhibitors (TKIs), some patients still have inferior outcomes. There are many …

Mutations in the drug binding region of BCR-ABL lead to imatinib resistance during the
management of chronic myeloid leukemia (CML). In our study, 62 Philadelphia positive …

Purpose: The aim of this study was to search the BCR/ABL 1 fusion gene in 45 chronic
myeloid leukemia (CML) Syrian patients using nested reverse transcription polymerase …

Background Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm
characterized by the presence of BCR‐ABL fusion gene (GenBank accession NC_000022 …

Background Depending on breakpoints of rearrangement different types of BCR–ABL fusion
protein can be generated in patients of chronic myeloid leukemia (CML). The aim of this …

Chronic myeloid leukemia (CML) is the most common myeloproliferative disorder among
chronic neoplasms. The history of this disease joins with the development of cytogenetic …

Aim In chronic myeloid leukemia (CML), the impact of MBCR-ABL1 major transcript type on
disease phenotype and response to treatment still controversial to date. This work aims to …

Summary Objectives: To evaluate the Clinico hematological profile based on the age, sex
and Clinico hematological presentations and frequencies of three phases of chronic myeloid …

Purpose The introduction and success of imatinib mesylate have become a paradigm shift in
chronic myeloid leukemia (CML) treatment. However, despite its high efficiency, resistance …